Nektar Therapeutics (NKTR) to Release Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is anticipated to announce its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.69) per share and revenue of $10.4390 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Nektar Therapeutics Stock Up 4.4%

Shares of NKTR stock opened at $71.11 on Thursday. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -8.92 and a beta of 1.17. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $75.67. The firm’s 50 day moving average price is $49.49 and its two-hundred day moving average price is $51.07.

Insider Activity

In related news, CEO Howard W. Robin sold 423 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total value of $137,935.89. Following the transaction, the insider directly owned 21,354 shares in the company, valued at approximately $761,697.18. The trade was a 15.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 4,470 shares of company stock worth $181,955. 5.25% of the stock is owned by corporate insiders.

Institutional Trading of Nektar Therapeutics

Large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in Nektar Therapeutics by 336.9% during the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Prosight Management LP purchased a new stake in Nektar Therapeutics in the 4th quarter worth approximately $23,450,000. Two Sigma Investments LP boosted its stake in shares of Nektar Therapeutics by 446.9% during the 3rd quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after buying an additional 354,842 shares during the period. Invesco Ltd. grew its holdings in shares of Nektar Therapeutics by 106.3% during the 4th quarter. Invesco Ltd. now owns 468,159 shares of the biopharmaceutical company’s stock valued at $19,794,000 after acquiring an additional 241,262 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Nektar Therapeutics by 30.0% during the 3rd quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock valued at $53,978,000 after acquiring an additional 219,155 shares in the last quarter. 75.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on NKTR. Piper Sandler restated an “overweight” rating and set a $105.00 price objective on shares of Nektar Therapeutics in a research note on Monday, January 26th. William Blair raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Citigroup began coverage on shares of Nektar Therapeutics in a research note on Wednesday, November 26th. They issued a “buy” rating and a $102.00 target price on the stock. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $126.29.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.